Sebti SM - Search Results

1

The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.

Ohkanda J, Blaskovich MA, Sebti SM, Hamilton AD. Ohkanda J, et al. Among authors: sebti sm. Prog Cell Cycle Res. 2003;5:211-7. Prog Cell Cycle Res. 2003. PMID: 14593715 Review.

2

Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.

Sun J, Ohkanda J, Coppola D, Yin H, Kothare M, Busciglio B, Hamilton AD, Sebti SM. Sun J, et al. Among authors: sebti sm. Cancer Res. 2003 Dec 15;63(24):8922-9. Cancer Res. 2003. PMID: 14695209

3

Farnesyltransferase inhibitors as anticancer agents: current status.

Zhu K, Hamilton AD, Sebti SM. Zhu K, et al. Among authors: sebti sm. Curr Opin Investig Drugs. 2003 Dec;4(12):1428-35. Curr Opin Investig Drugs. 2003. PMID: 14763128 Review.

4

Protein farnesyltransferase: flexible docking studies on inhibitors using computational modeling.

Guida WC, Hamilton AD, Crotty JW, Sebti SM. Guida WC, et al. Among authors: sebti sm. J Comput Aided Mol Des. 2005 Dec;19(12):871-85. doi: 10.1007/s10822-005-9030-2. Epub 2006 May 12. J Comput Aided Mol Des. 2005. PMID: 16607571

5

Targeting protein prenylation for cancer therapy.

Berndt N, Hamilton AD, Sebti SM. Berndt N, et al. Among authors: sebti sm. Nat Rev Cancer. 2011 Oct 24;11(11):775-91. doi: 10.1038/nrc3151. Nat Rev Cancer. 2011. PMID: 22020205 Free PMC article.

6

Inhibitors of protein farnesyltransferase as novel anticancer agents.

Ohkanda J, Knowles DB, Blaskovich MA, Sebti SM, Hamilton AD. Ohkanda J, et al. Among authors: sebti sm. Curr Top Med Chem. 2002 Mar;2(3):303-23. doi: 10.2174/1568026023394281. Curr Top Med Chem. 2002. PMID: 11944822 Review.

7

Inhibitors of prenyl transferases.

Sebti S, Hamilton AD. Sebti S, et al. Curr Opin Oncol. 1997 Nov;9(6):557-61. doi: 10.1097/00001622-199711000-00011. Curr Opin Oncol. 1997. PMID: 9370077 Review.

8

Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.

Lerner EC, Hamilton AD, Sebti SM. Lerner EC, et al. Among authors: sebti sm. Anticancer Drug Des. 1997 Jun;12(4):229-38. Anticancer Drug Des. 1997. PMID: 9199657 Review.

9

Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.

Sun J, Qian Y, Hamilton AD, Sebti SM. Sun J, et al. Among authors: sebti sm. Oncogene. 1998 Mar;16(11):1467-73. doi: 10.1038/sj.onc.1201656. Oncogene. 1998. PMID: 9525745

10

Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.

Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, Sebti SM. Sun J, et al. Among authors: sebti sm. Cancer Res. 1999 Oct 1;59(19):4919-26. Cancer Res. 1999. PMID: 10519405

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

293 results

Search Page

Filters